Status:
RECRUITING
Profiling of Circulating Immune Cells to Uncover Response Signatures to Anti-PD1 Immunotherapy in Melanoma Patients
Lead Sponsor:
University Hospital, Grenoble
Collaborating Sponsors:
Etablissement Français du Sang
Conditions:
Melanoma
Eligibility:
All Genders
18+ years
Brief Summary
Despite being standard of care, there are still many medical requirements related to immune checkpoint blocker based therapies such as identify patients susceptible to respond with the less adverse ev...
Eligibility Criteria
Inclusion
- Patient with histologically confirmed melanoma (stage I, II, III or IV based on AJCC classification)
- Able to sign the informed collection consent for the retrospective part or to express their non-opposition to the research for the prospective part of the study
Exclusion
- Subject under guardianship or subject deprived of freedom
- Persons benefiting from special protection (as defined in Articles L1121-5 and L1121-8 of the Public Health Code): minors, pregnant or breastfeeding women, adults protected by law (under guardianship, curatorship or deprived of liberty) and persons hospitalized without their consent (as defined in Articles L3212-1 and L3212-3 of the Public Health Code).
- ocular melanoma
Key Trial Info
Start Date :
January 17 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2031
Estimated Enrollment :
707 Patients enrolled
Trial Details
Trial ID
NCT06154668
Start Date
January 17 2024
End Date
January 1 2031
Last Update
February 20 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU Grenoble Alpes
Grenoble, France, 38043